{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Sicca+Syndrome&page=4",
    "query": {
      "condition": "Sicca Syndrome",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 73,
    "total_pages": 8,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Sicca+Syndrome&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Sicca+Syndrome&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-13T14:52:34.813Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02254265",
      "title": "Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Keratoconjunctivitis Sicca",
        "Dry Eye Disease"
      ],
      "interventions": [
        {
          "name": "OTX-101 0.05%",
          "type": "DRUG"
        },
        {
          "name": "OTX-101 0.09%",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sun Pharmaceutical Industries Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 455,
      "start_date": "2014-09",
      "completion_date": "2015-05",
      "has_results": true,
      "last_update_posted_date": "2022-08-29",
      "last_synced_at": "2026-11-13T14:52:34.813Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02254265"
    },
    {
      "nct_id": "NCT01213342",
      "title": "Omega-3 Fatty Acid Supplements and Dry Eye",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Keratoconjunctivitis Sicca"
      ],
      "interventions": [
        {
          "name": "Omega-3 Fatty Acid",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Soybean Soft Gels",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Ohio State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2010-05",
      "completion_date": "2011-07",
      "has_results": false,
      "last_update_posted_date": "2012-03-20",
      "last_synced_at": "2026-11-13T14:52:34.813Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01213342"
    },
    {
      "nct_id": "NCT01900249",
      "title": "To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Keratoconjunctivitis Sicca"
      ],
      "interventions": [
        {
          "name": "R348 Ophthalmic Solution, 0.2%",
          "type": "DRUG"
        },
        {
          "name": "R348 Ophthalmic Solution, 0.5%",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rigel Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 204,
      "start_date": "2013-07",
      "completion_date": "2014-07",
      "has_results": true,
      "last_update_posted_date": "2016-10-03",
      "last_synced_at": "2026-11-13T14:52:34.813Z",
      "location_count": 20,
      "location_summary": "Artesia, California • Petaluma, California • Rancho Cardova, California + 16 more",
      "locations": [
        {
          "city": "Artesia",
          "state": "California"
        },
        {
          "city": "Petaluma",
          "state": "California"
        },
        {
          "city": "Rancho Cardova",
          "state": "California"
        },
        {
          "city": "Parker",
          "state": "Colorado"
        },
        {
          "city": "Brandon",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01900249"
    },
    {
      "nct_id": "NCT02139033",
      "title": "A Phase 4 Study Investigating the Efficacy of Retaine™ in Managing Signs and Symptoms Associated With Dry Eye Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Keratoconjunctivitis Sicca"
      ],
      "interventions": [
        {
          "name": "Retaine™",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ocusoft, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2014-05",
      "completion_date": "2014-05",
      "has_results": false,
      "last_update_posted_date": "2014-06-11",
      "last_synced_at": "2026-11-13T14:52:34.813Z",
      "location_count": 1,
      "location_summary": "Andover, Massachusetts",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02139033"
    },
    {
      "nct_id": "NCT05918406",
      "title": "Phase 4 Study Evaluating the Safety of the Nasal Guide With Tyrvaya",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Dry Eye",
        "Keratoconjunctivitis Sicca"
      ],
      "interventions": [
        {
          "name": "Nasal Guide",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Oyster Point Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2023-06-14",
      "completion_date": "2023-08-18",
      "has_results": true,
      "last_update_posted_date": "2025-05-06",
      "last_synced_at": "2026-11-13T14:52:34.813Z",
      "location_count": 2,
      "location_summary": "Edison, New Jersey • Woodland Park, New Jersey",
      "locations": [
        {
          "city": "Edison",
          "state": "New Jersey"
        },
        {
          "city": "Woodland Park",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05918406"
    },
    {
      "nct_id": "NCT01843894",
      "title": "A Phase 1/2, RU-101 Ophthalmic Solution in Patients With Severe Dry Eye",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye"
      ],
      "interventions": [
        {
          "name": "RU-101",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "R-Tech Ueno, Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 104,
      "start_date": "2013-04",
      "completion_date": "2014-07",
      "has_results": false,
      "last_update_posted_date": "2019-09-11",
      "last_synced_at": "2026-11-13T14:52:34.813Z",
      "location_count": 1,
      "location_summary": "Norfolk, Virginia",
      "locations": [
        {
          "city": "Norfolk",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01843894"
    },
    {
      "nct_id": "NCT05310422",
      "title": "Safety Study of Tivanisiran to Treat Dry Eye",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dry Eye Disease"
      ],
      "interventions": [
        {
          "name": "Tivanisiran sodium ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "Vehicle ophthalmic solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sylentis, S.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 301,
      "start_date": "2022-03-24",
      "completion_date": "2023-10-11",
      "has_results": true,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-11-13T14:52:34.813Z",
      "location_count": 25,
      "location_summary": "Chandler, Arizona • Phoenix, Arizona • Glendale, California + 21 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Hemet",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05310422"
    },
    {
      "nct_id": "NCT02798289",
      "title": "Acute Tear Production Following Single Use of the Oculeve Intranasal Neurostimulator",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Dry Eye Syndrome",
        "Keratoconjunctivitis Sicca"
      ],
      "interventions": [
        {
          "name": "Oculeve Intranasal Neurostimulator",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Oculeve, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2016-06",
      "completion_date": "2016-08",
      "has_results": true,
      "last_update_posted_date": "2017-10-25",
      "last_synced_at": "2026-11-13T14:52:34.813Z",
      "location_count": 2,
      "location_summary": "Artesia, California • Newport Beach, California",
      "locations": [
        {
          "city": "Artesia",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02798289"
    },
    {
      "nct_id": "NCT01547936",
      "title": "Effect of Controlled Adverse Environment (CAE) on Tear Film Stability",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Keratoconjunctivitis Sicca"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "ORA, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2012-02",
      "completion_date": "2012-02",
      "has_results": false,
      "last_update_posted_date": "2012-03-08",
      "last_synced_at": "2026-11-13T14:52:34.813Z",
      "location_count": 1,
      "location_summary": "Andover, Massachusetts",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01547936"
    },
    {
      "nct_id": "NCT00201955",
      "title": "Study of Rebamipide Eye Drops to Treat Dry Eye",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Keratoconjunctivitis Sicca"
      ],
      "interventions": [
        {
          "name": "Rebamipide 1%",
          "type": "DRUG"
        },
        {
          "name": "Rebamipide 2%",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 762,
      "start_date": "2004-05-01",
      "completion_date": "2006-07-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-24",
      "last_synced_at": "2026-11-13T14:52:34.813Z",
      "location_count": 60,
      "location_summary": "Birmingham, Alabama • Flagstaff, Arizona • Little Rock, Arkansas + 47 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Flagstaff",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Inglewood",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00201955"
    }
  ]
}